

FOR IMMEDIATE RELEASE

MEDIA CONTACT: Farah Qureshi, (703) 885-0269

HDMA APPLAUDS PASSAGE OF FEDERAL PHARMACEUTICAL TRACEABILITY LEGISLATION BY HOUSE ENERGY AND COMMERCE COMMITTEE

ARLINGTON, Va., May 15, 2013 — HDMA President and CEO John M. Gray released the following statement on the passage of the Safeguarding America's Pharmaceuticals Act of 2013 — H.R. 1919, sponsored by Representatives Bob Latta (R-Ohio) and Jim Matheson (D-Utah) — out of the House Energy and Commerce Committee today:

“We are pleased that Congress is closer to enacting a bipartisan solution to protect patient safety and enhance the efficiency of the healthcare supply chain; the passage of this bill today through the House Energy and Commerce Committee is an important step in that direction. We praise Congressmen Latta and Matheson and their fellow co-sponsors for introducing this legislation, as it offers a comprehensive, practical approach to increase safety, and creates efficiencies and certainty for the industry by eliminating the current patchwork of competing state requirements. HDMA hopes that the momentum behind this effort will continue, and we urge Congress to pass this critical legislation this year.”

About HDMA

HDMA is the national association representing primary healthcare distributors, the vital link between the nation's pharmaceutical manufacturers and healthcare providers. Each business day, HDMA member companies ensure that nine million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDMA and its members work daily to provide value and achieve cost savings, an estimated \$42 billion each year to our nation's healthcare system. For more information, visit www.HealthcareDistribution.org. ###